Drug intelligence / Profile preview

MY001 (Mengyang Pharmaceutical)

Development stage: Preclinical
Lead developer: Monyan Pharmaceutical

Overview

MY001 is an unnamed **Class 3.1 Traditional Chinese Medicine ancient classic formula** being developed by Monyan Pharmaceutical for tumor-related supportive care. The company’s R&D pipeline identifies MY001 as clinically trial-exempt and states that a marketing-approval application was planned for 2025; the formula’s botanical composition, dosage form, route of administration, molecular targets, and specific pharmacologic mechanism have not been publicly disclosed. ([en.monyan.cn](https://en.monyan.cn/index.php/lists/65.html))

Beyond the preview

Go deeper on MY001 (Mengyang Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY001 (Mengyang Pharmaceutical).

Explore the full profile